The Split-Second Decision Impacting 500M+ People
“I could either hit him, or lay the thing down,” recalled renowned surgeon Dr. Gaetano Scuderi of the fateful motorcycle accident that changed everything.
The seven-year hiatus from surgery that followed didn’t just change his life. It may help more than 500M people suffering from osteoarthritis, because it led to the creation of Cytonics.
Cytonics developed what could be the first and only treatment that’s shown the ability to reverse the effects of osteoarthritis, the world’s most common cause of joint pain. This therapy attacks the root cause of the disease, potentially offering a solution Big Pharma has chased for years.
But that's only scratching the surface of why 7,000+ investors have already backed Dr. Scuderi's vision.
- Breakthrough: If approved, CYT-108 could be the first therapy in history to actually halt cartilage destruction and promote regrowth.
- Traction: $32M raised from 7,000+ investors, including a seven-figure investment from pro athletes Rener and Eve Gracie, backed by partnerships with Stanford and Scripps Research.
- Opportunity: Everyday investors have the limited-time chance to participate in an early-stage biotech investment opportunity that’s historically been reserved for VCs and institutional investors.
Providing true relief is a massive opportunity in the $560B osteoarthritis treatment market. Even better, you can join them as an investor at the pre-certification stage and unlock exclusive rewards like up to 15% bonus stock.
This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/
Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal